CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER
|Bid procedure, 2021-04-28|
|Certificate||Commercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of|
Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after
|Bids||Counterparties may make one bid per Credit rating class and maturity class.|
Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.
|Bid times||09.00-09.30 (CET/CEST) on the Bid date|
|Requested volume (corresponding nominal amount)||SEK 4 billion|
|Highest permitted bid volume (corresponding nominal amount)||The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion.|
No bid may contain Commercial paper in excess of SEK 250 million issued by the same issuer.
|Lowest permitted bid volume (corresponding nominal amount)||The total bid volume from one Counterparty should not be less than SEK 100 million and not be less than SEK 20 million per Commercial paper (ISIN code).|
|Credit rating classes||The requested volume is divided into two credit rating classes. Credit rating refers to the issuer’s credit rating. Credit rating may also refer to the issuer’s parent company in cases where the issuer has no own credit rating and the parent company guarantees the issuer’s obligations. If there are credit ratings from several credit rating agencies the highest of these will be applied. If there are both a long term and a short term credit rating the highest of these will be applied.|
Class 1: No less than a long-term credit rating of A- with S&P, A3 with Moody’s, A- with Fitch, A- with Nordic Credit Rating or A- with Scope, or no less than a short-term credit rating of A-2 with S&P, P-2 with Moody’s, F2 with Fitch or N-1+ with Nordic Credit Rating.
Class 2: No less than a long-term credit rating of BBB- with S&P, Baa3 with Moody’s, BBB- with Fitch, BBB- with Nordic Credit Rating or BBB- with Scope or no less than a short-term credit rating of A-3 with S&P, P-3 with Moody’s, F3 with Fitch or N-1 with Nordic Credit Rating.
However, no credit rating may be lower than the lowest accepted credit rating level. There must also be no indication on the Bid Date that a credit rating may fall below the lowest accepted credit rating level.
|Price (purchase rate)||Certificates with a remaining maturity of up to three months on the Bid date. i.e. with the latest maturity date as of|
Class 1: 0.30 per cent
Class 2: 0.60 per cent
Certificates with a remaining maturity of up to six months on the Bid date, i.e. with the latest maturity date as of
Class 1: 0.40 per cent
Class 2: 0.70 per cent
|Expected allocation time||Not later than 10.00 (CET/CEST) on the Bid date|
|Delivery and payment date||2021-04-30|
|Delivery of Commercial paper||To the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383|
|General terms and conditions||General terms and conditions for the Riksbank´s purchases of commercial papers via bid procedures 2020:1. dated 30 March 2020 (see the Riksbank´s web).|
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Mandalay Resources Corporation Announces Financial Results for the First Quarter of 202113.5.2021 00:05:33 CEST | Press release
TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) is pleased to announce its financial results for the quarter March 31, 2021. The Company’s condensed and consolidated interim financial results for the quarter ended March 31, 2021, together with its Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under the Company’s profile on www.sedar.com and on the Company’s website at www.mandalayresources.com. All currency references in this press release are in U.S. dollars except as otherwise indicated. First Quarter 2021 Highlights: Quarterly revenue of $52.6 million; highest since Q2 2016;Adjusted EBITDA of $26.1 million; third highest in Company’s history;Adjusted net income of $5.6 million ($0.06 or C$0.08 per share); andConsolidated net income of $25.5 million ($0.28 or C$0.35 per share). Dominic Duffy, President and CEO of Mandalay, commented: “Mandalay Resources is ple
Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy12.5.2021 22:29:11 CEST | Press release
LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the release of preliminary data relating to the use of a novel cell therapy approach in controlling human immunodeficiency virus (HIV) in humans. Dr. Serhat Gumrukçu, co-founder and inventor of Enochian BioSciences and Director of the Seraph Research Institute (SRI), presented the findings at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Presentation can be found at https://www.enochianbio.com/about-us/collaborations/ A 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy. With approval from an Institutional Review Board, this single patient was treated with a novel cellular therapy of natural killer (NK) and gamma delta T-cells (GDT) – a small subset of immune cells that can be infected with HIV but coul
Inventiva reports first quarter 2021 financial information and updates on the collaboration with AbbVie in auto-immune diseases12.5.2021 22:00:00 CEST | Press release
Cash and cash equivalents at €107.8m as of March 31, 2021 Revenues of €0.1m in Q1 2021Decision by AbbVie to move into Phase IIb clinical development with cedirogant in psoriasis, following promising results in its Phase Ib clinical trial Daix (France), May 12, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today reported its cash position as of March 31, 2021 and its revenues for the first quarter of 2021, and provided an update on its collaboration with AbbVie in auto-immune diseases. Cash Position As of March 31, 2021, Inventiva’s cash and cash equivalents stood at €107.8 million compared to €113.0 million as of December 31, 2020. Net cash used in operating activities amounted to €7.8 million in the first quarter of 2021 compared to €3.6
TGS Shares received by Board of Directors12.5.2021 21:27:41 CEST | Press release
OSLO, Norway (12 May 2021) - The Annual General Meeting of TGS held on 11 May 2021, approved that each of the Directors, other than the Chairman, should receive 1650 restricted shares in the Company as part of their compensation. The shares were transferred to the Directors on 12 May 2021. The attachment shows the number of restricted shares awarded on 11 May 2021 and the total number of shares held by each of the Directors. The Company has distributed the restricted shares to the Directors from its balance of treasury shares. Following the transfer of restricted shares to the Directors, TGS will hold 225,100 of the issued shares as treasury shares. About TGS TGS provides scientific data and intelligence to companies active in the energy sector. In addition to a global, extensive and diverse energy data library, TGS offers specialized services such as advanced processing and analytics alongside cloud-based data applications and solutions. Forward Looking Statement All statements in thi
Leasinvest Real Estate intends to become an integrated real estate group through an envisaged business combination with Extensa Group and by giving up its BE-REIT status12.5.2021 19:13:09 CEST | Press release
JAN SUYKENS, CEO ACKERMANS & VAN HAAREN CHAIRMAN LEASINVEST RE: “AvH, which owns today both 30.01% of LRE and 100% of Extensa, is pleased to be able to support the evolution of the Company’s strategy as proposed by its management. Through the contribution of our stake in Extensa, we strengthen our commitment to LRE and we support the intended strategic evolution towards a mixed real estate investment and development group.” MICHEL VAN GEYTE, CEO LEASINVEST RE: “’Leasinvest 2.0’ will become a real estate player with a unique market position that combines the best of both worlds: recurring rental income from real estate investments and added value potential from development activities. In addition, ‘Leasinvest 2.0’ will operate from a thorough sustainability vision in which it will make a lasting contribution to the development and optimization of its real estate portfolio in Belgium, the Grand Duchy of Luxemburg and Austria.” A unique combination Leasinvest Real Estate (the “Company”) a
Volta Finance Limited - Net Asset Value as at 30 April 202112.5.2021 18:17:42 CEST | Press release
Volta Finance Limited (VTA / VTAS) –April2021 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 12May2021 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for April. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY Volta has continued to perform well with +2.1% in April, reaching a total return of 8.4% for the first four months of 2021. In April, Volta paid €0.14 per share dividend to shareholders (circa 8% annualized yield), a €0.02 increase relative to the January dividend payment, evidencing the improving situation of Volta. This time around, the performance was driven almost evenly by the solid performance from CLO equity and CLO debt tranches. This month, contrary to March, the USD depreciation cost almost 1% of the monthly performance. The monthly
Idorsia holds its Annual General Meeting of Shareholders12.5.2021 18:09:53 CEST | Press release
Allschwil, Switzerland – May12, 2021 All Board proposals approved by the Shareholders At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Allschwil, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with a large majority. The meeting was held in accordance with the requirements of the COVID‑19 Ordinance 3, issued by the Swiss Federal Council. As a result, attendance in person was not possible and voting took place by independent proxy. In total, 4,541 shareholders voted through the independent proxy, representing a total of 112,170,657 shares, or 67.13% of the total outstanding shares. Mathieu Simon, MD, Chairman of the Board of Directors of Idorsia, commented: “Despite the global pandemic, Idorsia looks back on an incredibly successful year and the future promises to not lose any momentum. The coming year will be crucial as we continue to build the foundation of Idorsia's future. I am very proud to have been re-elected as your C